Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial

BACKGROUND: In the primary analysis of the PREDICT trial, a higher hemoglobin target (11–13 g/dl) with darbepoetin alfa did not improve renal outcomes compared with a lower hemoglobin target (9–11 g/dl) in advanced chronic kidney disease (CKD) without diabetes. Prespecified secondary analyses were p...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Shoichi, Kurasawa, Shimon, Hayashi, Terumasa, Nangaku, Masaomi, Narita, Ichiei, Hirakata, Hideki, Tanabe, Kenichiro, Morita, Satoshi, Tsubakihara, Yoshiharu, Imai, Enyu, Akizawa, Tadao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432358/
https://www.ncbi.nlm.nih.gov/pubmed/37289335
http://dx.doi.org/10.1007/s10157-023-02362-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432358/
https://www.ncbi.nlm.nih.gov/pubmed/37289335
http://dx.doi.org/10.1007/s10157-023-02362-w

Ejemplares similares